Treatable Traits in Interstitial Lung Disease

The goal of this clinical trial is to learn if a personalised treatment model of care "treatable traits" can improve quality of life and disease progression in patients with interstitial lung disease. The main question it aims to answer is, will providing a treatable traits model of care improve health-related quality of life (HRQoL) (primary outcome), symptoms, anxiety, physical activity, and body composition (secondary outcomes). Researchers will compare the treatable traits model to standard of care. Participants in both arms will complete surveys, a Dual-Energy X-Ray Absorptiometry (DEXA) and whole-body composition scan, lung function and blood tests. Those in the intervention (TT) arm will be seen in a multidisciplinary clinic where they are seen by an ILD doctor, physiotherapist, psychologist, and dietitian.

NCT Number	NCT06626438
Lead Sponsor	The University of Western Australia Collaborators: Fiona Stanley Hospital, Sir Charles Gairdner Hospital
Conditions	Interstitial Lung Diseases (ILD)
Enrollment	110 participants
Start Date	2025-09-03
Primary Completion	2026-12 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2025-10-07